<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04549038</url>
  </required_header>
  <id_info>
    <org_study_id>2019-1180</org_study_id>
    <nct_id>NCT04549038</nct_id>
  </id_info>
  <brief_title>Time Restricted Nutrition in Pediatric Stem Cell Transplant Recipients</brief_title>
  <official_title>Time Restricted Nutrition in Pediatric Stem Cell Transplant Recipients: Impact on Circadian Rhythm, Insulin Regulation, and Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Circadian cycles, metabolism, and nutrition are intimately linked, and the timing of meals&#xD;
      play an important role in synchronizing peripheral circadian rhythms. There are little data&#xD;
      describing the influence of nocturnal feeds on sleep, metabolism, and overall health in&#xD;
      hospitalized children. To evaluate this association, the investigators will conduct a&#xD;
      single-center, randomized, non-blinded controlled trial that will test the impact of&#xD;
      nocturnal enteral/parenteral nutrition on patient outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HSCT provides a potential cure for children and adults with high risk and relapsed&#xD;
      malignancy, immune deficiency, and other fatal illnesses. Circadian cycles, metabolism, and&#xD;
      nutrition are intimately linked, and the timing of meals play an important role in&#xD;
      synchronizing peripheral circadian rhythms; however, the standard of care for HSCT recipients&#xD;
      is to deliver continuous feeds (either enterally or parenterally).&#xD;
&#xD;
      The objective of this study is to evaluate the influence of the timing of feeding on sleep&#xD;
      and metabolism in HSCT subjects. The investigators hypothesize patients receiving feeds&#xD;
      during daytime hours (0800-2000) in comparison to continuous (24 hours), will have improved&#xD;
      sleep efficiency, decreased blood glucose, insulin, and triglycerides over patients who&#xD;
      receive feeding overnight. The aim of this study is to evaluate the influence of the timing&#xD;
      of feeds on sleep, metabolism, and outcomes in HSCT subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 19, 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 randomized, non-blinded, controlled</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of wake episodes</measure>
    <time_frame>21 days</time_frame>
    <description>Number of wake episodes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of wake episodes</measure>
    <time_frame>21 days</time_frame>
    <description>Duration of wake episodes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypertension</measure>
    <time_frame>21 days</time_frame>
    <description>Incidence of hypertension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight change</measure>
    <time_frame>21 days</time_frame>
    <description>Change in weight at day +7, +14, and +21 from day 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tolerating oral feeds</measure>
    <time_frame>21 days</time_frame>
    <description>Number of days post-transplant until the patient tolerates feeds/nutrition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophil engraftment</measure>
    <time_frame>21 days</time_frame>
    <description>Time to absolute neutrophil count &gt;500</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortisol levels</measure>
    <time_frame>21 days</time_frame>
    <description>3 times weekly morning cortisol levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceride levels</measure>
    <time_frame>21 days</time_frame>
    <description>Weekly triglyceride levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose levels</measure>
    <time_frame>21 days</time_frame>
    <description>Daily glucose levels</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hematopoietic Stem Cell Transplant</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the cases group will receive their nutrition over a period of 12-16 hours, with minimum 8 hours of fasting and maximum 12 hours of fasting. All patients will receive 100% of their daily nutrition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients randomized to the control group will receive the current standard of care (24-hour continuous nutrition). All patients will receive 100% of their daily nutrition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>12-16 hour nutrition</intervention_name>
    <description>Cases will receive their nutrition over a period of 12-16 hours, with minimum 8 hours of fasting and maximum 12 hours of fasting. Feeding will begin in morning hours unless otherwise directed by an investigator or registered dietician.</description>
    <arm_group_label>Cases</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients &gt;/= 12 months of age undergoing HSCT and receiving a myeloablative&#xD;
             preparative regimen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior history of hypoglycemia, diabetes mellitus, metabolic disease, or other&#xD;
             requirement for continuous nutrition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Dandoy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christopher Dandoy</last_name>
    <phone>513-636-7287</phone>
    <email>Christopher.Dandoy@cchmc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Dandoy</last_name>
      <phone>513-636-7287</phone>
      <email>Christopher.Dandoy@cchmc.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 8, 2020</study_first_submitted>
  <study_first_submitted_qc>September 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

